S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

OTCMKTS:NRIFF - Nuvo Pharmaceuticals Stock Price, Forecast & News

$0.34
0.00 (-0.03 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$0.34
Now: $0.34
$0.34
50-Day Range
$0.27
MA: $0.36
$0.50
52-Week Range
$0.24
Now: $0.34
$2.01
Volume2,020 shs
Average Volume6,140 shs
Market Capitalization$3.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Nuvo Pharmaceuticals Inc., a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NRIFF
CUSIPN/A
CIKN/A
Phone905-673-6980

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.43 million
Book Value$1.40 per share

Profitability

Net Income$-4,750,000.00

Miscellaneous

Employees97
Market Cap$3.87 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive NRIFF News and Ratings via Email

Sign-up to receive the latest news and ratings for NRIFF and its competitors with MarketBeat's FREE daily newsletter.


Nuvo Pharmaceuticals (OTCMKTS:NRIFF) Frequently Asked Questions

What is Nuvo Pharmaceuticals' stock symbol?

Nuvo Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NRIFF."

How were Nuvo Pharmaceuticals' earnings last quarter?

Nuvo Pharmaceuticals Inc (OTCMKTS:NRIFF) released its quarterly earnings data on Thursday, October, 31st. The company reported $0.01 EPS for the quarter. The business earned $14.26 million during the quarter. Nuvo Pharmaceuticals had a negative net margin of 1.56% and a negative return on equity of 43.73%. View Nuvo Pharmaceuticals' Earnings History.

When is Nuvo Pharmaceuticals' next earnings date?

Nuvo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Nuvo Pharmaceuticals.

Has Nuvo Pharmaceuticals been receiving favorable news coverage?

News coverage about NRIFF stock has trended somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Nuvo Pharmaceuticals earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Nuvo Pharmaceuticals.

Who are some of Nuvo Pharmaceuticals' key competitors?

Who are Nuvo Pharmaceuticals' key executives?

Nuvo Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert Paul Harris, Exec. Chairman (Age 64)
  • Mr. Jesse F. Ledger, Pres & CEO
  • Ms. Mary-Jane E. Burkett CPA-CA, HBA, VP & CFO
  • Ms. Katina K. Loucaides M.Sc., LL.B, VP, Corp. Sec. & Gen. Counsel
  • Mr. Calogero Lunetta MSc, VP of Manufacturing

How do I buy shares of Nuvo Pharmaceuticals?

Shares of NRIFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nuvo Pharmaceuticals' stock price today?

One share of NRIFF stock can currently be purchased for approximately $0.34.

How big of a company is Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals has a market capitalization of $3.87 million and generates $15.43 million in revenue each year. Nuvo Pharmaceuticals employs 97 workers across the globe.View Additional Information About Nuvo Pharmaceuticals.

What is Nuvo Pharmaceuticals' official website?

The official website for Nuvo Pharmaceuticals is http://www.nuvopharmaceuticals.com/.

How can I contact Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals' mailing address is 6733 MISSISSAUGA ROAD SUIT 610, MISSISSAUGA A6, L5N 6J5. The company can be reached via phone at 905-673-6980 or via email at [email protected]


MarketBeat Community Rating for Nuvo Pharmaceuticals (OTCMKTS NRIFF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Nuvo Pharmaceuticals and other stocks. Vote "Outperform" if you believe NRIFF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRIFF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel